2025
Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials
Armstrong A, Kircik L, Stein Gold L, Strober B, De Oliveira C, Vaile J, Jou Y, Daamen C, Scharnitz T, Lebwohl M. Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials. Dermatology And Therapy 2025, 15: 1025-1035. PMID: 40113724, PMCID: PMC11971090, DOI: 10.1007/s13555-025-01362-w.Peer-Reviewed Original ResearchLaboratory adverse eventsLaboratory parametersAdverse eventsLong-term extensionPlaque psoriasisModerate to severe plaque psoriasisSevere plaque psoriasisDouble-blind trialTyrosine kinase 2 inhibitorTreatment of adultsJanus kinaseSystemic therapyClinically meaningful changeDeucravacitinibPsoriasis trialsPatientsIncidence rateHigh gradePlaceboApremilastMeaningful changePsoriasisTrialsGradePhase 3
2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
Korman N, Warren R, Bagel J, Armstrong A, Gooderham M, Strober B, Thaçi D, Morita A, Imafuku S, Foley P, Sofen H, Zheng M, Hippeli L, Kisa R, Banerjee S, Blauvelt A. Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. Journal Of Dermatological Treatment 2024, 35: 2371045. PMID: 38945549, DOI: 10.1080/09546634.2024.2371045.Peer-Reviewed Original ResearchConceptsMaintenance of responseModerate to severe plaque psoriasisOnset of actionSevere plaque psoriasisPlaque psoriasisApremilast-treated patientsEfficacy measuresOral placeboClinical responseCoprimary endpointsDeucravacitinibPsoriasis trialsWeek 8PlaceboPASIPatientsWeek 1WeeksEfficacyPsoriasisSPGABaselineSignificant improvementTrialsApremilast
2019
Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials
Perez-Chada LM, Gottlieb AB, Cohen J, Mease P, Duffin KC, Garg A, Latella J, Armstrong AW, Ogdie A, Merola JF. Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. Journal Of The American Academy Of Dermatology 2019, 82: 54-61. PMID: 31163240, DOI: 10.1016/j.jaad.2019.05.075.Peer-Reviewed Original ResearchConceptsPsA symptomsPsoriasis trialsOutcome measuresConsensus meetingPatient Index Data 3International Dermatology Outcome MeasuresPatient association representativesPsoriatic Arthritis ImpactPsoriatic arthritis symptomsPsoriasis clinical trialsAppropriate outcome measuresConsensus-building studyDelphi surveyPSA screeningArthritis ImpactArthritis symptomsPsoriatic arthritisDisease 9Psoriasis studiesClinical trialsTrial participantsSymptomsQuality appraisalAcceptable alternativeData 3
2017
Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis
Papp K, Bachelez H, Blauvelt A, Winthrop K, Romiti R, Ohtsuki M, Acharya N, Braun D, Mallbris L, Zhao F, Xu W, Walls C, Strober B. Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis. British Journal Of Dermatology 2017, 177: 1537-1551. PMID: 28600810, DOI: 10.1111/bjd.15723.Peer-Reviewed Original ResearchConceptsIncidence rateTreatment groupsInfection rateSpecific infection rateSevere psoriasisSerious infectionsExposure-adjusted incidence ratesIRs of infectionsMonoclonal antibodiesWeeks of treatmentOverall infection rateIncidence of infectionOesophageal candidiasisBiological therapyPsoriasis trialsAntifungal therapyClinical trialsIxekizumabCandida infectionsPatientsLong-term exposureInfectionPsoriasisIncidenceTrials
2013
Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up
Papp K, Griffiths C, Gordon K, Lebwohl M, Szapary P, Wasfi Y, Chan D, Hsu M, Ho V, Ghislain P, Strober B, Reich K, 1 P. Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up. British Journal Of Dermatology 2013, 168: 844-854. PMID: 23301632, DOI: 10.1111/bjd.12214.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedCardiovascular DiseasesClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDermatologic AgentsDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansInfectionsMaleMiddle AgedNeoplasmsPsoriasisRandomized Controlled Trials as TopicUstekinumabConceptsAdverse eventsSevere psoriasisGeneral U.S. populationSerious AEsOverall mortalityRate of AEsOverall adverse eventsSerious adverse eventsAEs of interestU.S. populationLong-term safetyLong-term safety evaluationPatient management decisionsUstekinumab doseUstekinumab exposureDose groupMore dosesPsoriasis trialsSerious infectionsSafety dataCumulative toxicityCumulative exposurePsoriasisPatientsEvent rates
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply